Gut Metabolites Unlocked: New Hope for Diabetes, Obesity
A breakthrough research project, supported by FAPESP and conducted at Harvard University, has identified specific metabolites originating from the gut that travel via the hepatic portal vein to the liver, then to the heart, influencing metabolic pathways and insulin sensitivity throughout the body. Published in Cell Metabolism, these findings offer promising new avenues for treating obesity and type 2 diabetes by understanding the intricate gut-liver-heart axis.
The research, led by Vitor Rosetto Muñoz and guided by Carl Ronald Kahn, uniquely analyzed blood samples from both the hepatic portal vein (draining the intestine to the liver) and peripheral circulation. This approach allowed for precise observation of gut microbiome-derived metabolite enrichment at each site, offering a clearer picture than traditional fecal or peripheral blood analyses. Scientists increasingly recognize the gut microbiome‘s crucial role in metabolic disorders, yet identifying specific microbial products and their interactions has remained a significant challenge.
The study revealed that in healthy mice, 111 metabolites were enriched in the hepatic portal vein, a number that drastically decreased to 48 in genetically predisposed mice fed a high-fat diet. This highlights the profound impact of environmental factors like diet and host genetics on metabolite profiles, suggesting complex interactions with the gut microbiome that mediate conditions like obesity and metabolic syndrome. Different metabolite combinations are directed to the liver and peripheral circulation based on these interactions.
Further investigation involved treating susceptible mice with antibiotics to modify their microbiome, leading to altered metabolite balances. Notably, this increased the presence of mesaconate, a metabolite involved in the Krebs cycle. When liver cells (hepatocytes) were treated with mesaconate and its isomers, researchers observed improved insulin signaling and regulated genes crucial for controlling hepatic fat accumulation (lipogenesis) and fatty acid oxidation. These discoveries underscore the critical role of gut-derived metabolites in liver metabolism and the pathogenesis of diet-related type 2 diabetes and insulin resistance, paving the way for identifying novel therapeutic options.
